SU

239

-3.22%↓

BAS

48.21

+1.95%↑

AM

319.4

-3.68%↓

REP

23.13

+1.4%↑

EXE.US

111.77

+3.99%↑

SU

239

-3.22%↓

BAS

48.21

+1.95%↑

AM

319.4

-3.68%↓

REP

23.13

+1.4%↑

EXE.US

111.77

+3.99%↑

SU

239

-3.22%↓

BAS

48.21

+1.95%↑

AM

319.4

-3.68%↓

REP

23.13

+1.4%↑

EXE.US

111.77

+3.99%↑

SU

239

-3.22%↓

BAS

48.21

+1.95%↑

AM

319.4

-3.68%↓

REP

23.13

+1.4%↑

EXE.US

111.77

+3.99%↑

SU

239

-3.22%↓

BAS

48.21

+1.95%↑

AM

319.4

-3.68%↓

REP

23.13

+1.4%↑

EXE.US

111.77

+3.99%↑

Search

Eurofins Scientific SE

Deschisă

60.92 -1.42

Rezumat

Modificarea prețului

24h

Curent

Minim

60.8

Maxim

62.26

Indicatori cheie

By Trading Economics

Venit

105M

228M

Vânzări

1.9B

3.7B

P/E

Medie Sector

24.031

66.822

Randament dividend

1.17

Marjă de profit

6.2

Angajați

65,694

EBITDA

285M

693M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+20.22% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

1.17%

3.56%

Următoarele câștiguri

25 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.7B

11B

Deschiderea anterioară

62.34

Închiderea anterioară

60.92

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Eurofins Scientific SE Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mar. 2026, 23:47 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar. 2026, 22:55 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar. 2026, 21:51 UTC

Achiziții, Fuziuni, Preluări

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar. 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mar. 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar. 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Global Equities Roundup: Market Talk

23 mar. 2026, 22:42 UTC

Market Talk
Evenimente importante

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar. 2026, 22:40 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar. 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar. 2026, 22:21 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar. 2026, 22:20 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar. 2026, 22:19 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar. 2026, 22:18 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar. 2026, 22:15 UTC

Achiziții, Fuziuni, Preluări

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar. 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mar. 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar. 2026, 21:32 UTC

Câștiguri

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar. 2026, 21:10 UTC

Evenimente importante

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar. 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mar. 2026, 20:50 UTC

Market Talk
Câștiguri
Evenimente importante

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Eurofins Scientific SE Așteptări

Obiectiv de preț

By TipRanks

20.22% sus

Prognoză pe 12 luni

Medie 73.43 EUR  20.22%

Maxim 81 EUR

Minim 64 EUR

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEurofins Scientific SE - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

2

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

54.22 / 56.82Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Eurofins Scientific SE

Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of various analytical methods and tests to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, healthcare and cosmetics, and food supplements; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include sustainability, expert services and regulatory, consumer research and sensory evaluation, audits, testing, certifications and approvals, inspections, and training courses for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; food irradiation and labelling, heavy metals, carbohydrates, radioactivity, nutritional analysis, microbiolody, and testing for persistent organic pollutants, veterinary drug residue, dioxins and organic contaminants, pesticides, mycotoxins, and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and other services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
help-icon Live chat